Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AORT stock price vs ZBH: inconclusive — current versus $5.47 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZBH's multiple
Implied fair value · at AORT's multiple
Needs AORT P/E.
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ARTIVION, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ZIMMER BIOMET HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
AORT vs ABT
Merck & Co., Inc.
AORT vs MRK
BOSTON SCIENTIFIC CORP
AORT vs BSX
JOHNSON & JOHNSON
AORT vs JNJ
TELEFLEX INC
AORT vs TFX
STRYKER CORP
AORT vs SYK
Medtronic plc
AORT vs MDT
Orthofix Medical Inc.
AORT vs OFIX
SMITH & NEPHEW PLC
AORT vs SNN
CONMED Corp
AORT vs CNMD
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AORT can sustain double-digit revenue growth while converting its 64.4% gross margin into materially higher operating and net margins, then holding or accumulating may be justified because the current premium is being paid for future margin expansion rather than current earnings power.
On a P/E basis, AORT screens far richer than ZBH at 127.8x versus 26.5x, which is why the simple implied price point comes out far below the current price. However, the comparison is distorted by AORT’s much smaller earnings base and faster growth, so the gap is not as straightforward as the headline downside implies.
Supporting Metrics
